--- title: "MediciNova: Differentiated NAFLD/MASH Profile and Complementary APOC3 Positioning Support Unchanged $6 Target and Buy Rating" type: "News" locale: "en" url: "https://longbridge.com/en/news/293670592.md" description: "Maxim Group analyst Jason McCarthy maintained a Buy rating and $6 price target for MediciNova. He cited the company's differentiated NAFLD/MASH profile and MN-001's multi-mechanistic approach as complementary to APOC3 therapies, rather than competitive. The upcoming Phase 2 readout in mixed populations is highlighted as a key catalyst. Additionally, H.C. Wainwright also maintained a Buy rating with a $10 price target." datetime: "2026-07-23T21:25:21.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293670592.md) - [en](https://longbridge.com/en/news/293670592.md) - [zh-HK](https://longbridge.com/zh-HK/news/293670592.md) generator: "portal-rs" --- # MediciNova: Differentiated NAFLD/MASH Profile and Complementary APOC3 Positioning Support Unchanged $6 Target and Buy Rating Medicinova, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $6.00 price target. ### Claim 55% Off TipRanks - Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions - Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks Jason McCarthy has given his Buy rating due to a combination of factors tied to MediciNova’s differentiated profile in metabolic disease. He notes that recent Phase 3 success by Arrowhead in severe hypertriglyceridemia validates APOC3 biology and the commercial potential of triglyceride-lowering therapies, while simultaneously underscoring that triglyceride reduction alone does not address liver fat or liver enzyme abnormalities. In this context, MN-001’s oral, multi-mechanistic approach, which has shown the ability to lower both triglycerides and liver fat and to raise HDL in a diabetic NAFLD population, positions it for a potentially broader role in NAFLD/MASH with coexisting hypertriglyceridemia and type 2 diabetes. McCarthy also highlights the upcoming Phase 2 readout in this mixed population as a key catalyst and argues that MN-001 is complementary rather than directly competitive to APOC3 agents, supporting his unchanged $6 price target and Buy recommendation. McCarthy covers the Healthcare sector, focusing on stocks such as Medicinova, Inmune Bio, and AIM ImmunoTech. According to TipRanks, McCarthy has an average return of -13.0% and a 30.06% success rate on recommended stocks. In another report released on July 15, H.C. Wainwright also maintained a Buy rating on the stock with a $10.00 price target. ### Related Stocks - [MNOV.US](https://longbridge.com/en/quote/MNOV.US.md) - [ARWR.US](https://longbridge.com/en/quote/ARWR.US.md) - [INMB.US](https://longbridge.com/en/quote/INMB.US.md) - [AIM.US](https://longbridge.com/en/quote/AIM.US.md) - [4875.JP](https://longbridge.com/en/quote/4875.JP.md) - [AIMID.US](https://longbridge.com/en/quote/AIMID.US.md) - [AIMI.US](https://longbridge.com/en/quote/AIMI.US.md) ## Related News & Research - [MediciNova CEO Iwaki base salary rises to $690,246 under new employment agreement](https://longbridge.com/en/news/296348115.md) - [Analyst Reiterates Buy on MediciNova as Advancing Pipeline and Upcoming ALS Catalysts Support Unchanged $6 Price Target](https://longbridge.com/en/news/291454858.md) - [Buy Rating Reaffirmed on Litigation Progress, Price Target Maintained at $5900](https://longbridge.com/en/news/296601286.md) - [21:24 ETCaliway's CBL-514 Combination Therapy Cleared by U.S. FDA for Phase 2 Trial; Pivotal Phase 3 Trial SUPREME-01 Initiates Enrollment](https://longbridge.com/en/news/296970484.md) - [Can Komzifti's Early Adoption Support Kura Oncology's Next Phase Of Growth?](https://longbridge.com/en/news/296928079.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**